Galapagos halts lupus CAR-T program, confirms 100 layoffs so far this year

[cafead]

via Galapagos has never been afraid of reworking its pipeline or workforce to face the future. 2022 saw the Belgian biotech pivot to CAR-T therapies and then drop its kidney disease and fibrosis programs—the latter move coinciding with laying off 200 employees.

article source